These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7995052)

  • 21. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
    Cheng G; Tian F; Li Y
    Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Impact of cyclin-dependent kinase inhibitor p27 on resistance of ovarian cancer multicellular spheroids to taxol].
    Xing H; Li J; Gao QL; Wu JH; Gao C; Lu YP; Ma D
    Zhonghua Yi Xue Za Zhi; 2003 Jan; 83(1):37-41. PubMed ID: 12757643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
    Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
    J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of the ATP-cell viability assay for assessment of in vitro radiation treatment response in gynecologic cancer cell lines.
    Rodriguez M; Steren AJ
    Contrib Gynecol Obstet; 1994; 19():156-65. PubMed ID: 7995047
    [No Abstract]   [Full Text] [Related]  

  • 26. Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
    Busschots S; O'Toole S; O'Leary JJ; Stordal B
    Exp Cell Res; 2015 Aug; 336(1):1-14. PubMed ID: 25499884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
    Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
    Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell line.
    Hata K; Osaki M; Dhar DK; Nakayama K; Fujiwaki R; Ito H; Nagasue N; Miyazaki K
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):68-74. PubMed ID: 14569416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting MyD88.
    Zhan Y; Xiang F; Wu R; Xu J; Ni Z; Jiang J; Kang X
    J Ovarian Res; 2015 Jul; 8():48. PubMed ID: 26223974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expression of COP9, JAK2, HSP and NADH in ovarian carcinoma tissues after taxol-chemotherapy and their significance].
    Li HX
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jul; 43(7):528-32. PubMed ID: 19080518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.
    Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN
    Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The identification of drug resistance in ovarian cancer and breast cancer: application of the MTT assay.
    Sargent J; Elgie A; Taylor CG; Wilson J; Alton P; Hill JG
    Contrib Gynecol Obstet; 1994; 19():64-75. PubMed ID: 7995054
    [No Abstract]   [Full Text] [Related]  

  • 36. Relationship of DNA ploidy to chemoresistance of tumors as measured by in vitro tests.
    Volm M; Efferth T
    Cytometry; 1990; 11(3):406-10. PubMed ID: 1971209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
    Baguley BC; Marshall ES; Whittaker JR; Dotchin MC; Nixon J; McCrystal MR; Finlay GJ; Matthews JH; Holdaway KM; van Zijl P
    Eur J Cancer; 1995; 31A(2):230-7. PubMed ID: 7718330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional regulation of chemokine expression in ovarian cancer.
    Singha B; Gatla HR; Vancurova I
    Biomolecules; 2015 Mar; 5(1):223-43. PubMed ID: 25790431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
    Csóka K; Tholander B; Gerdin E; de la Torre M; Larsson R; Nygren P
    Int J Cancer; 1997 Sep; 72(6):1008-12. PubMed ID: 9378534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneous interaction of interferon-beta and taxol in human ovarian cancer cells in vitro.
    Sen S; Zocchetti A; Beccaglia P; Balconi G; Erba E; D'Incalci M
    Eur J Cancer; 1994; 30A(6):892-3. PubMed ID: 7917558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.